European Urology Oncology Intensity of Active Surveillance and Transition to Treatment in Men with Low-risk Prostate Cancer  Henrik Olsson, Tobias Nordström, Mark Clements, Henrik Grönberg, Anna Wallerstedt Lantz, Martin Eklund  European Urology Oncology  DOI: 10.1016/j.euo.2019.05.005 Copyright © 2019 The Authors Terms and Conditions

Fig. 1 Flowchart of the study population. Low-risk PCa with AS indicated as the primary management option at diagnosis (AS cohort) and a second comparison group of low-risk PCa that did not undergo AS at diagnosis (non-AS group). AS=active surveillance; GS=Gleason score; NPCR=National Prostate Cancer Register; PCa=prostate cancer. European Urology Oncology DOI: (10.1016/j.euo.2019.05.005) Copyright © 2019 The Authors Terms and Conditions

Fig. 2 Proportion of individuals with PSA/biopsy by time on AS in the AS cohort. Frequencies of PSA testing and biopsies are described as the yearly proportion of individuals with a repeat PSA and repeat biopsy during follow-up of 10yr. The horizontal reference lines represent the yearly recommended testing according to the national guidelines. AS=active surveillance; PSA=prostate-specific antigen. European Urology Oncology DOI: (10.1016/j.euo.2019.05.005) Copyright © 2019 The Authors Terms and Conditions